Patents Examined by Ebenezer O. Sackey
  • Patent number: 10385023
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: August 20, 2019
    Assignee: CYTOKINETICS, INC.
    Inventors: Bradley Paul Morgan, Alex Muci, Pu-Ping Lu, Erica Anne Kraynack, Todd Tochimoto, David J. Morgans, Jr.
  • Patent number: 10383881
    Abstract: The present invention relates to 1,5-dihydro-2H-pyrrol-2-one compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells, including inducing the stem/progenitor cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into tissue cells.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: August 20, 2019
    Assignee: Frequency Therapeutics, Inc.
    Inventors: Christopher Loose, Bradley Tait, Rajesh Manchanda, Will McLean
  • Patent number: 10376511
    Abstract: The present invention provides pyrazole pyrimidine derivatives which inhibit Casein kinase I (CKI) and/or Interleukin-1 receptor-associated kinase 1 (IRAKI) and methods of their manufacture, compositions comprising them and uses thereof in methods of treating malignant disease and disorders and methods for treating inflammatory diseases and disorders.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: August 13, 2019
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem LTD.
    Inventors: Yinon Ben Neriah, Guy Brachya, Ido Burstain, Waleed Minzel, Irit Snir-Alkalay, Joseph Vacca, Dansu Li
  • Patent number: 10377738
    Abstract: This invention relates to pyridone derivatives, processes for their preparation, phamaceutical compositions, and their use in therapy.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: August 13, 2019
    Assignee: JANSSEN SCIENCES IRELAND UNLIMITED COMPANY
    Inventors: David Craig McGowan, Pierre Jean-Marie Bernard Raboisson
  • Patent number: 10358414
    Abstract: Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers? disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: July 23, 2019
    Assignee: Promentis Pharmaceuticals, Inc.
    Inventors: Michael Neary, James Nieman, Steven Tanis, Daniel Lawton, Garry Smith
  • Patent number: 10351822
    Abstract: The present invention relates compounds for stabilizing cells and methods of their use.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: July 16, 2019
    Assignee: The Scripps Research Institute
    Inventors: Yue Xu, Sheng Ding
  • Patent number: 10351531
    Abstract: Pyrazole derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the serotonin 5HT2A receptor. Formula (Ia). Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of insomnia and related sleep disorders, platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: July 16, 2019
    Assignee: ARENA PHARMACEUTICALS, INC.
    Inventors: Yifeng Xiong, Martin C. Cherrier, Jin Sun Karoline Choi, Peter I. Dosa, Brian M. Smith, Sonja Strah-Pleynet, Brett Ullman, Bradley Teegarden
  • Patent number: 10336726
    Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt or hydrate thereof, useful as a CGRP receptor antagonist.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: July 2, 2019
    Assignee: Eli Lilly and Company
    Inventors: Jennifer Anne McMahon, Miles Goodman Siegel, Russell Dean Stucky
  • Patent number: 10326083
    Abstract: A compound of Chemical Formula 1, and an organic photoelectric device, an image sensor, and an electronic device including the same are disclosed: In Chemical Formula 1, each substituent is the same as defined in the detailed description.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: June 18, 2019
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Tadao Yagi, Xavier Bulliard, Hyesung Choi, Rie Sakurai, Hiromasa Shibuya, Youn Hee Lim, Sung Young Yun, Gae Hwang Lee, Kwang Hee Lee, Dong-Seok Leem
  • Patent number: 10316002
    Abstract: The invention relates to compounds and their use in the treatment of disease. Novel irreversible inhibitors of wild-type and mutant forms of EGFR, FGFR, ALK, ROS, JAK, BTK, BLK, ITK, TEC, and/or TXK and their use for the treatment of cell proliferation disorders are described.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: June 11, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael Gray, Hwan Geun Choi, Li Tan
  • Patent number: 10294218
    Abstract: Novel 4,6-disubstituted aminopyrimidine derivatives with the following structure (I) have anti-HIV activity.
    Type: Grant
    Filed: February 25, 2017
    Date of Patent: May 21, 2019
    Assignee: VIROSTATICS SRL
    Inventors: Franco Lori, James Chafouleas, Davide De Forni, Antonio Solinas, Zoltán Varga, Zoltán Greff, László Õrfi, György Kéri
  • Patent number: 10292960
    Abstract: The present invention relates to an anticancer agent having a high safety and a superior anticancer activity, and an anticancer agent containing, as an active ingredient, an aminoacetonitrile compound represented by the formula (I) wherein R1 is a hydrogen atom, an alkyl group and the like, R2, R3, and R4 are the same or different and each is a hydrogen atom, an alkyl group and the like, R5 and R6 are the same or different and each is a hydrogen atom, a halogen atom and the like, m is 0 or 1, R is a halogen atom, a cyano group, a nitro group, a phenyl group optionally substituted by an alkyl group and the like, an alkyl group and the like, Ar1 is a phenyl group, a naphthyl group, a pyridyl group, a pyrazolyl group, or the like, each of which is optionally substituted by a halogen atom, a cyano group, a nitro group, alkyl group and the like, and W is —O—, —S—, —SO2—, or —N(R7)— wherein R7 is a hydrogen atom, a (C1-C6) alkyl group and the like, or a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: May 21, 2019
    Assignee: PITNEY PHARMACEUTICALS PTY LIMITED
    Inventors: Nobuharu Andoh, Osamu Sanpei, Tetsuo Toga, David Morris, Roger Aston, Koji Tanaka, Tomokazu Hino
  • Patent number: 10294227
    Abstract: A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, (Formula (I)) wherein: R1 is (CH2)mNR11R12; R2 is selected from H, halo, OR13, NHR13, alkyl, alkenyl and alkynyl; R3 is selected from alkyl, alkenyl, alkynyl, aryl, halo, aryloxy, NHCO2R4, NHCONR5R6, NHCOR7, NH-alkyl, NH-alkenyl, NH(CH2);n-aryl, (CH2)p-heteroaryl, (CH2)qCO2R8, (CH2)rCOR9 and NHSO2R10, wherein each alkyl, alkenyl, aryl or heteroaryl moiety in the aforementioned list is optionally further substituted by one or more groups selected from alkyl, halo OH, NH2, alkoxy, aryloxy, alkylamino, arylamino, carboxyl and carboxamide; R4 to R10 and R13 are each independently selected from alkyl, alkenyl and aryl; R11 and R12 are each independently selected from alkyl and alkenyl; or R11 and R:12 are linked together with the nitrogen to which they are attached to form a heterocycloalkyl or heterocycloalkenyl group; n, m, p, q and r are each independently selected from 0, 1, 2, 3, 4, 5
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: May 21, 2019
    Assignee: UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH
    Inventors: Asier Unciti-Broceta, Craig Fraser, Neil O. Carragher
  • Patent number: 10294236
    Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung c
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: May 21, 2019
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Mui Cheung, Michael P. Demartino, Hilary Schenck Eidam, Huiping Amy Guan, Donghui Qin, Chengde Wu, Zhen Gong, Haiying Yang, Haiyu Yu, Zhiliu Zhang
  • Patent number: 10287268
    Abstract: The present disclosure provides imidazolyl compounds of Formula (I) and methods of preparing the compounds. The provided compounds are able to bind protein kinases and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase in a subject or cell and/or in treating or preventing a disease (e.g., proliferative disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: May 14, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, Hwan Geun Choi, Yanke Liang
  • Patent number: 10272030
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: April 30, 2019
    Assignee: Cytokinetics, Inc.
    Inventors: Zhe Yang, Alex R. Muci, Jeffrey Warrington, Gustave Bergnes, Bradley P. Morgan, Chihyuan Chuang, Antonio Romero, Scott Collibee, Xiangping Qian, Pu-Ping Lu
  • Patent number: 10272085
    Abstract: This invention relates to pyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections such as HCV or HBV.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: April 30, 2019
    Assignee: Janssen Sciences Ireland UC
    Inventors: David McGowan, Pierre Jean-Marie Bernard Raboisson, Werner Embrechts, Tim Hugo Maria Jonckers, Stefaan Julien Last, Serge Maria Aloysius Pieters, Jaromir Vlach
  • Patent number: 10266542
    Abstract: The present invention relates to compounds that inhibit EZH2 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: April 23, 2019
    Assignee: Mirati Therapeutics, Inc.
    Inventors: Matthew Arnold Marx, Matthew Randolph Lee, Robert Anthony Galemmo, Thomas P. Bobinski
  • Patent number: 10266497
    Abstract: Provided herein are pyrazole compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of monoacylglycerol lipase (MAGL). Furthermore, the subject compounds and compositions are useful for the treatment of pain.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: April 23, 2019
    Assignee: ABIDE THERAPEUTICS, INC.
    Inventors: Cheryl A. Grice, John J. M. Wiener, Olivia D. Weber, Katharine K. Duncan
  • Patent number: 10253001
    Abstract: The present invention discloses a method for preparing azoxystrobin intermediates represented by formulae (1) and (2), comprising: controlling a compound represented by formula (3) to contact with sodium methoxide and 4,6-dichloropyrimidine, to obtain a mixture of intermediates represented by formulae (1) and (2), in the existence of a catalyst, the catalyst is an azabicyclic compound or its salt. The present invention further discloses a method for preparing azoxystrobin, comprising: controlling the intermediate represented by formula (2) provided in the present invention to react with 2-cyanophenol or its salt under the catalytic action of an azabicyclic compound or its salt, to obtain an azoxystrobin compound represented by formula (4). The method provided in the present invention has advantages including high transformation ratio, high product purity, easy and convenient operation, and environmental friendliness.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: April 9, 2019
    Assignees: Nutrichem Company Limited, Shangyu Nutrichem Co., LTD.
    Inventors: Jianwei Chen, Wenjun Wang, Jianhong Chi, Yongchang Zhao, Xufang Deng, Long Wang, Wentao Jin, Guobin Chen